Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2606-2617

  Witzig, Thomas E ^a   Silberstein, Peter T ^a   Loprinzi, Charles L ^a   Sloan, Jeff A ^a   Novotny, Paul J ^a   Mailliard, James A ^a   Rowland, Kendrith M ^a   Alberts, Steven R ^a   Krook, James E ^a   Levitt, Ralph ^a   Morton, Roscoe F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN BETA CHAIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TOXICITY; TREATMENT RESPONSE; BLOOD TRANSFUSION; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 21044442522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.020     Document Type: Article

References (45)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer lnst 91:1616-1634, 1999
2. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990
3. Beguin Y, Yerna M, Loo M, et al: Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648-653, 1992
4. Timm M, Kimlinger TK, Hanson C, et al: Measurement of the cell proliferation rate of bone marrow erythroid precursors by flow cytometry: Initial applications to multiple myeloma. Leuk Lymphoma 30:353-359, 1998
5. Cella D, Davis K, Breitbart W, et al: Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385-3391, 2001
6. Cella D, Lai JS, Chang CH, et al: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94:528-538, 2002
7. Crawford J, Cella D, Cleeland CS, et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895, 2002
8. Abels R: Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A:S2-S8, 1993
9. Cascinu S, Fedeli A, Del Ferro E, et al: Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12:1058-1062, 1994
10. Case DC Jr, Bukowski RM, Carey RW, et al: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801-806, 1993
11. Henry D, Abels R: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21:21-28, 1994 (suppl 3)
12. Littlewood TJ: Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy. Front Radiat Ther Oncol 37:34-37, 2002
13. Osterborg A, Brandberg Y, Molostova V, et al: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494, 2002
14. Garton J, Gertz M, Witzig T, et al: Epoetin alfa for the treatment of the anemia of multiple myeloma. Arch Intern Med 155:2069-2074, 1995
15. Oberhoff C, Neri B, Amadori D, et al: Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 9:255-260, 1998
16. Osterborg A, Boogaerts M, Cimino R, et al: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: A randomized multicenter study-The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87:2675-2682, 1996
17. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
18. Littlewood TJ, Nortier J, Rapoport B, et al: Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 21:169-180, 2003
19. Rutherford CJ, Schneider TJ, Dempsey H, et al: Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: The importance of iron availability in optimizing response. Am J Med 96:139-145, 1994
20. Goldberg M, McCutchen J, Jove M, et al: A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 25:544-552, 1996
21. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
22. Ludwig H, Fritz E, Leitgeb C, et al: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063, 1994
23. Sloan JA, Loprinzi CL, Kuross SA, et al: Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 16:3662-3673, 1998
24. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
25. McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1:373-378, 1978
26. Varecchia CG, McCabe MS, Trimble E, et al: Quality of life in clinical cancer trials, I. J Natl Cancer Inst Monogr 20:vii-viii, 1996
27. Degner L, Sloan J: Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 10:423-431, 1995
28. Moinpour CM, Feigl P, Metch B, et al: Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 81:485-495, 1989
29. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320, 2002
30. Turner R, Anglin P, Burkes R, et al: Epoetin alfa in cancer patients: Evidence-based guidelines. J Pain Symptom Manage 22:954-965, 2001
31. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study-Procrit Study Group. J Clin Oncol 16:3412-3425, 1998
32. Dunphy FR, Dunleavy TL, Harrison BR, et al: Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 79:1623-1628, 1997
33. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 15:1218-1234, 1997
34. Quirt I, Robeson C, Lau CY, et al: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126-4134, 2001
35. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990
36. Ludwig H, Pecherstorfer M, Leitgeb C, et al: Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells 11:348-355, 1993
37. Ludwig H, Fritz E, Leitgeb C, et al: Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4:161-167, 1993
38. Ludwig H, Sundal E, Pecherstorfer M, et al: Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76:2319-2329, 1995
39. Platanias LC, Miller CB, Mick R, et al: Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9:2021-2026, 1991
40. Glaspy JA, Jadeja JS, Justice G, et al: A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97:1312-1320, 2003
41. Cella D, Zagari MJ, Vandoros C, et al: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373, 2003
42. Jatoi A, Kumar S, Sloan J, et al: On appetite and its loss. J Clin Oncol 18:2930-2932, 2000
43. Casadevall N, Nataf J, Viron B, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
44. Littlewood TJ, Bajetta E, Mortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
45. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715, 2001